lenalidomide

P2, N=144, Not yet recruiting, Sun Yat-sen University

P2, N=24, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

Treatment with low-dose Len in transfusion-independent del(5q) MDS reduced the mutational burden of most genes and did not promote the expansion of preexisting clones or AML progression, especially TP53-mutated clones. Early administration of Len in del(5q) MDS patients without TD may be an effective therapeutic approach with a manageable safety profile regarding clonal evolution.

P1/2, N=35, Not yet recruiting, Odense University Hospital

P1, N=106, Completed, Alliance for Clinical Trials in Oncology | Phase classification: P2 --> P1

P3, N=1226, Not yet recruiting, University of Leeds

P1/2, N=78, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | N=38 --> 78

P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended

Mezigdomide-carfilzomib-dexamethasone provided a significant PFS benefit compared with carfilzomib-dexamethasone alone, with higher rates of grade 3 or 4 adverse events, including infections, which were mostly manageable with standard clinical practice and supportive care. These findings support mezigdomide-carfilzomib-dexamethasone as a clinically meaningful treatment option as early as first relapse in predominantly triple-class-exposed, anti-CD38 antibody-refractory and lenalidomide-refractory patients, a growing population with substantial unmet need.

P2, N=1, Completed, Centre Hospitalier Universitaire, Amiens | Recruiting --> Completed | N=114 --> 1

P2, N=30, Completed, Northwestern University | Active, not recruiting --> Completed

Fixed-duration epcoritamab monotherapy showed promising complete response rates and a manageable safety profile in older adults with newly diagnosed DLBCL and comorbidities, with slight differences between stages 1 and 2. Continued investigation of epcoritamab as a first-line chemotherapy-free treatment option is warranted.